CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) Updates 2025 expected revenue range to $1.5 to 2.5 billion Expects ...

Research analysts at Leerink Partnrs issued their Q4 2025 earnings estimates for Moderna in a research note issued to ...

Research analysts at Leerink Partnrs cut their FY2024 earnings estimates for shares of Moderna in a note issued to investors ...

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the developme ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Up to 21 million people contract norovirus each year in the U.S. alone, the CDC says.

Investors in Moderna Inc (Symbol ... publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would ...

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...